Cabot Wealth Management Inc. Has $5.48 Million Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Cabot Wealth Management Inc. raised its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 5.6% during the 4th quarter, Holdings Channel reports. The institutional investor owned 16,496 shares of the company’s stock after acquiring an additional 871 shares during the quarter. Cabot Wealth Management Inc.’s holdings in Medpace were worth $5,480,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Arcadia Investment Management Corp MI bought a new position in shares of Medpace in the 4th quarter valued at about $72,000. Prakash Investment Advisors LLC bought a new position in Medpace in the fourth quarter valued at approximately $571,000. O Brien Greene & Co. Inc acquired a new position in shares of Medpace during the 4th quarter worth approximately $4,265,000. Ieq Capital LLC raised its stake in shares of Medpace by 1,090.6% during the 4th quarter. Ieq Capital LLC now owns 27,206 shares of the company’s stock worth $9,039,000 after purchasing an additional 24,921 shares in the last quarter. Finally, Private Advisor Group LLC boosted its holdings in shares of Medpace by 53.8% in the 4th quarter. Private Advisor Group LLC now owns 2,227 shares of the company’s stock valued at $740,000 after buying an additional 779 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

Medpace Stock Performance

NASDAQ MEDP opened at $340.78 on Friday. Medpace Holdings, Inc. has a 52-week low of $302.01 and a 52-week high of $459.77. The stock has a market cap of $10.38 billion, a PE ratio of 26.98, a P/E/G ratio of 3.81 and a beta of 1.36. The firm has a 50-day moving average of $343.13 and a 200-day moving average of $347.20.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Robert W. Baird boosted their target price on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Medpace currently has a consensus rating of “Hold” and an average price target of $381.44.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.